Last reviewed: June 8, 2026
Last updated: June 8, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Two distinct medication classes have emerged as evidence-backed options for weight management: bupropion, an antidepressant that increases norepinephrine and dopamine, and GLP-1 receptor agonists, which regulate appetite hormones. Each addresses obesity through separate neurochemical mechanisms, and recent clinical data shows meaningful differences in weight reduction magnitude and side effect profiles between them.
How Bupropion Works for Weight Loss
Bupropion is an atypical antidepressant originally developed to treat depression and seasonal affective disorder. The medication increases activity of norepinephrine and dopamine in the brain—neurotransmitters linked to appetite suppression, motivation, and metabolism. Unlike selective serotonin reuptake inhibitors (SSRIs), which often cause weight gain as a side effect, bupropion has a neutral to slightly weight-reducing profile.
Clinical trials of bupropion monotherapy show average weight losses of 5 to 10 pounds over 6 to 12 months. The mechanism relies on stimulating the hypothalamus and reducing hunger signals rather than mimicking hormonal pathways. Bupropion is often prescribed off-label for weight management, though the FDA has not approved it as a standalone weight-loss drug. Some physicians combine bupropion with naltrexone (Contrave), an approved combination, to enhance results through synergistic brain pathways.
GLP-1 Medications: A Different Pathway to Weight Loss
GLP-1 receptor agonists—including semaglutide and tirzepatide—mimic glucagon-like peptide-1, a natural hormone that regulates blood sugar and appetite. When these medications activate GLP-1 receptors in the brain and gut, they slow gastric emptying, increase feelings of fullness, and reduce cravings for food. This hormone-based mechanism differs fundamentally from bupropion's neurotransmitter approach.
Clinical trials demonstrate significantly greater weight loss with GLP-1 drugs compared to bupropion alone. Semaglutide trials showed average weight reductions of 10 to 15 pounds over 68 weeks, while tirzepatide—a dual GIP/GLP-1 receptor agonist—achieved weight losses of 15 to 22 pounds in similar timeframes. GLP-1 medications also improve cardiovascular outcomes and reduce type 2 diabetes risk, offering benefits beyond weight reduction.
Weight Loss Efficacy: Comparing Clinical Outcomes
Head-to-head efficacy data clearly favors GLP-1 medications over bupropion monotherapy. A 2023 clinical review found that GLP-1 receptor agonists produced weight loss approximately two to three times greater than bupropion alone, with sustained results when treatment continued. Bupropion remains more modest in its weight-reduction capacity, typically producing 5 to 10 pounds of loss in the first year.
Individual response varies based on genetic factors, baseline metabolism, and adherence patterns. Some patients experience robust weight loss with bupropion due to underlying dopamine-sensitive appetite regulation, while others show minimal response. PlexusDx Precision Peptide Genetic Test identifies your genetic predisposition across 14 metabolic pathways and 49 peptides, helping clinicians predict which medication class may yield the strongest outcome for your unique biology.
Side Effects and Tolerability Profiles
Bupropion's side effect profile includes insomnia, dry mouth, headache, and increased blood pressure in some patients. Because it stimulates the central nervous system, bupropion may cause anxiety or restlessness in sensitive individuals. The medication carries a black-box warning for increased seizure risk and is contraindicated in patients with seizure disorders or eating disorders.
GLP-1 medications typically cause gastrointestinal side effects—nausea, vomiting, constipation, and diarrhea—especially during dose escalation. These effects diminish over 2 to 4 weeks in most patients as the body adjusts. GLP-1 drugs do not carry seizure risk or cause stimulant-like side effects. Both medication classes require medical supervision, but GLP-1 medications have a well-established safety profile when prescribed by qualified clinicians through licensed 503A compounding pharmacies like those partnered with PlexusDx.
Is Combination Therapy an Option?
Some research has explored combining bupropion with GLP-1 medications to leverage both pathways—dopamine stimulation plus hormone-mediated appetite suppression. Limited published data exists on this combination, and safety protocols require careful monitoring of blood pressure and neurological symptoms. Combination approaches remain largely experimental and require prescriber expertise.
PlexusDx offers Compounded Semaglutide Injection starting at $149 per month and Oral Semaglutide starting at $249 per month, allowing flexible dosing tailored to your response. For patients interested in dual-pathway support, PlexusDx also provides GLP-Squared (combined semaglutide and tirzepatide injection) starting at $249 per month. All medications are dispensed from licensed 503A compounding pharmacies, with no insurance requirement and HSA/FSA eligibility.
Choosing Between Bupropion and GLP-1: Key Considerations
The choice between bupropion and GLP-1 medications depends on several factors: your target weight loss amount, tolerance for gastrointestinal side effects, medical history (especially seizure risk), and baseline mental health status. If you seek modest weight loss (5 to 10 pounds) and have depression or low mood, bupropion may be appropriate. If you aim for substantial weight reduction (15+ pounds) and want cardiovascular benefits, GLP-1 medications typically deliver superior outcomes.
Genetic testing refines this decision. PlexusDx Precision Peptide Genetic Test identifies your variants in GLP1R, GIPR, FTO, MC4R, and 10 additional metabolic genes, revealing whether your biology is primed for GLP-1 receptor responsiveness or dopamine-pathway sensitivity. This personalized data allows your clinician to match medication to your genetic predisposition, maximizing efficacy and minimizing unnecessary trial-and-error dosing.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I take bupropion and GLP-1 medications together?
Combination therapy remains largely experimental with limited published safety data. Some clinicians may consider it under close monitoring, but this approach requires specialized expertise and careful blood pressure tracking. PlexusDx recommends discussing any combination plan with a qualified prescriber who can order baseline labs and adjust dosing carefully.
How much weight can I expect to lose with bupropion versus GLP-1?
Bupropion monotherapy typically results in 5 to 10 pounds of weight loss over 12 months. GLP-1 medications produce substantially greater results—10 to 22 pounds depending on the specific drug (semaglutide versus tirzepatide) and individual factors. Your genetic predisposition, measured through the PlexusDx Precision Peptide Genetic Test, helps predict which medication class aligns with your metabolism.
What is the cost of GLP-1 medications through PlexusDx?
PlexusDx Compounded Semaglutide Injection starts at $149 per month, and Oral Semaglutide starts at $249 per month—your dose may need to go up, but your price won't. All medications are dispensed from licensed 503A compounding pharmacies, require no insurance, and are HSA/FSA eligible. The optional Precision Peptide Genetic Test costs $99 and identifies your genetic response patterns.
Does bupropion increase seizure risk?
Yes, bupropion carries a black-box warning for increased seizure risk, especially at higher doses or in patients with seizure history, eating disorders, or brain injury. GLP-1 medications do not carry this risk. If you have a personal or family history of seizures, GLP-1 medications are the safer choice for weight loss.
How does PlexusDx genetic testing help choose between these medications?
PlexusDx Precision Peptide Genetic Test maps your variants in GLP1R, GIPR, FTO, MC4R, and 10 additional genes across 14 metabolic pathways. These insights reveal whether your biology is optimized for GLP-1 receptor activation or dopamine-pathway sensitivity, allowing your clinician to select the medication class most likely to deliver results for your unique genetic profile.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Why Does Semaglutide Cause Diarrhea and How to Manage It Effectively
Can I Use HSA for Compounded Semaglutide? Understanding Your Options